Skip to main content

Histiocytosis Clinical Trials

 

Collaborative Clinical Trials

HLHRUXO: Ruxolitinib Therapy for HLH

HLHRUXO: Use of a Response-Adapted Ruxolitinib-containing Regimen for the Treatment of Hemophagocytic Lymphohistiocytosis

Diseases Treated:

Hemophagocytic Lymphohistiocytosis

Eligibility:

  • 6 weeks to 22 years old
  • Newly diagnosed hemophagocytic lymphohistiocytosis (HLH)
  • Relapsed or refractory HLH
View Trial

HSESID: Database for HLH Immunodeficiency Disease

A Registry for Hemophagocytic Lymphohistiocytosis (HLH)

Eligibility:

  • Diagnosis of a primary immunodeficiency predisposed to hemophagocytic lymphohistiocytosis
  • Meets at least 4 of 8 diagnostic criteria for HLH as defined by the Histiocyte Society and is receiving HLH-directed therapy
  • High suspicion of isolated Central Nervous System-HLH and is receiving HLH-directed therapy
View Trial

LCH-IV: Clinical Trial for Children and Adolescents with Langerhans Cell Histiocytosis

International Collaborative Treatment Protocol for Children and Adolescents with Langerhans Cell Histiocytosis

Diseases Treated:

Langerhans cell histiocytosis

Eligibility:

  • Diagnosis of Langerhans cell histiocytosis
  • Younger than 18 years old
  • Meets inclusion criteria for the respective stratum

 

View Trial